Page last updated: 2024-12-11

chlorferron

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

chlorferron: metabolite of coumaphos [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5355079
CHEMBL ID589883
CHEBI ID38620
SCHEMBL ID1024770
MeSH IDM0307320

Synonyms (60)

Synonym
nsc 44204
unii-evi89ha9v3
evi89ha9v3 ,
nsc 24924
einecs 228-217-8
AN-829/40891487
nsc44204
nsc-44204
nsc24924
3-chloro-4-methyl-7-hydroxycoumarin
6174-86-3
chlorferone
7-hydroxy-4-methyl-3-chlorocoumarin
nsc-24924
2h-1-benzopyran-2-one, 3-chloro-7-hydroxy-4-methyl-
coumarin, 3-chloro-7-hydroxy-4-methyl-
3-chloro-7-hydroxy-4-methyl-2h-1-benzopyran-2-one
3-chloro-7-hydroxy-4-methyl-2-benzopyrone
chlorferron
CHEBI:38620 ,
OPREA1_070479
3-chloro-7-hydroxy-4-methyl-chromen-2-one
3-chloro-7-hydroxy-4-methyl-2h-chromen-2-one
3-chloro-7-hydroxy-4-methylcoumarin, 97%
AKOS000274050
CHEMBL589883 ,
3-chloro-7-hydroxy-4-methylchromen-2-one
inchi=1/c10h7clo3/c1-5-7-3-2-6(12)4-8(7)14-10(13)9(5)11/h2-4,12h,1h3
odzhldrqczxqfq-uhfffaoysa-
3-chloro-4-methyl-7-hydroxy-2h-2-chromenone
bdbm50305318
A833402
3-chloro-7-hydroxy-4-methyl coumarin
AM806572
FT-0615445
3-chloro-7-hydroxy-4-methylcoumarin
3-chloro-4-methylumbelliferone
umbelliferone, 3-chloro-4-methyl-
SCHEMBL1024770
STL477589
3-chloro-4-methyl-7-hydroxy coumarin
tox21_303840
dtxcid8031314
NCGC00357111-01
dtxsid8052724 ,
cas-6174-86-3
3-chloro-7-hydroxy-4-methyl-2h-chromen-2-one #
3-chloro-7-hydroxy-4-methylcoumarin, analytical standard
coumaphos alcohol metabolite
mfcd00006851
chlorferon
AS-50125
Q27117921
C3098
BCP31695
chlorferone;3-chloro-7-hydroxy-4-methyl-2h-chromen-2-one pound>>3-chloro-7-hydroxy-4-methylcoumarin
SB40436
O10991
EN300-21484
Z104499616
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
organochlorine compoundAn organochlorine compound is a compound containing at least one carbon-chlorine bond.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (18)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
acetylcholinesteraseHomo sapiens (human)Potency53.27700.002541.796015,848.9004AID1347395; AID1347398
hypoxia-inducible factor 1 alpha subunitHomo sapiens (human)Potency42.81973.189029.884159.4836AID1224846; AID1224894
SMAD family member 2Homo sapiens (human)Potency42.87630.173734.304761.8120AID1346859; AID1346924; AID1347035
SMAD family member 3Homo sapiens (human)Potency42.87630.173734.304761.8120AID1346859; AID1346924; AID1347035
GLI family zinc finger 3Homo sapiens (human)Potency32.50710.000714.592883.7951AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency26.54460.000221.22318,912.5098AID1259243; AID1259247; AID1259381
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency44.60970.000657.913322,387.1992AID1259377; AID1259378; AID1259394
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency55.55880.001022.650876.6163AID1224838; AID1224839; AID1224893
progesterone receptorHomo sapiens (human)Potency36.74660.000417.946075.1148AID1346784; AID1346795; AID1347036
retinoid X nuclear receptor alphaHomo sapiens (human)Potency25.57650.000817.505159.3239AID1159527; AID1159531
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency27.33950.001530.607315,848.9004AID1224841; AID1224848; AID1224849; AID1259403
pregnane X nuclear receptorHomo sapiens (human)Potency68.58960.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency51.52020.000229.305416,493.5996AID1259244; AID1259248
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency36.29180.057821.109761.2679AID1159526; AID1159528
Histone H2A.xCricetulus griseus (Chinese hamster)Potency126.79300.039147.5451146.8240AID1224845
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency48.55770.001557.789015,848.9004AID1259244
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency48.55770.001551.739315,848.9004AID1259244
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Testosterone 17-beta-dehydrogenase 3Homo sapiens (human)IC50 (µMol)0.10000.00261.76469.3000AID452459
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (4)

Processvia Protein(s)Taxonomy
androgen biosynthetic processTestosterone 17-beta-dehydrogenase 3Homo sapiens (human)
male genitalia developmentTestosterone 17-beta-dehydrogenase 3Homo sapiens (human)
testosterone biosynthetic processTestosterone 17-beta-dehydrogenase 3Homo sapiens (human)
steroid biosynthetic processTestosterone 17-beta-dehydrogenase 3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (4)

Processvia Protein(s)Taxonomy
estradiol 17-beta-dehydrogenase [NAD(P)] activityTestosterone 17-beta-dehydrogenase 3Homo sapiens (human)
testosterone dehydrogenase [NAD(P)] activityTestosterone 17-beta-dehydrogenase 3Homo sapiens (human)
testosterone 17-beta-dehydrogenase (NADP+) activityTestosterone 17-beta-dehydrogenase 3Homo sapiens (human)
17-beta-hydroxysteroid dehydrogenase (NADP+) activityTestosterone 17-beta-dehydrogenase 3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (4)

Processvia Protein(s)Taxonomy
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
endoplasmic reticulumTestosterone 17-beta-dehydrogenase 3Homo sapiens (human)
endoplasmic reticulum membraneTestosterone 17-beta-dehydrogenase 3Homo sapiens (human)
intracellular membrane-bounded organelleTestosterone 17-beta-dehydrogenase 3Homo sapiens (human)
endoplasmic reticulumTestosterone 17-beta-dehydrogenase 3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID456202Inhibition of rat intestinal alpha-glucosidase at 100 ug/mL after 5 mins by spectrophotometry2010Bioorganic & medicinal chemistry, Jan-01, Volume: 18, Issue:1
alpha-Glucosidase inhibitory antihyperglycemic activity of substituted chromenone derivatives.
AID452459Inhibition of human 17beta-HSD3 expressed in HeLa cells2010Bioorganic & medicinal chemistry letters, Jan-01, Volume: 20, Issue:1
Coumarins as novel 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for potential treatment of prostate cancer.
AID456203Inhibition of rat intestinal alpha-glucosidase after 5 mins by spectrophotometry2010Bioorganic & medicinal chemistry, Jan-01, Volume: 18, Issue:1
alpha-Glucosidase inhibitory antihyperglycemic activity of substituted chromenone derivatives.
AID456201Antioxidant activity assessed as DPPH radical scavenging activity at 25 ug/mL after 30 mins by spectrophotometry2010Bioorganic & medicinal chemistry, Jan-01, Volume: 18, Issue:1
alpha-Glucosidase inhibitory antihyperglycemic activity of substituted chromenone derivatives.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (14)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (21.43)18.7374
1990's1 (7.14)18.2507
2000's4 (28.57)29.6817
2010's5 (35.71)24.3611
2020's1 (7.14)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.58

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.58 (24.57)
Research Supply Index2.71 (2.92)
Research Growth Index5.29 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.58)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other14 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]